Objective：To investigate the effects of intraperitoneal drug perfusion for treating exudative tuberculous peritonitis. Methods：The clinical data of 69 patients with exudative tuberculous peritonitis treated in our hospital within three and a half years were analyzed retrospectively. Thirty-six cases in the observation group were given systemic antituberculotic therapy combined with intraperitoneal perfusion of isoniazid, mikacin and defibrase. The other 33 cases in control group received systemic antituberculotic tharapy only. The indexes including duration of fever, time for abdominal pain remission and ascites elimination, and incidence rate of intestinal obstruction between two groups after treatment was compared. The levels of C-reactive protein (CRP), adenosine deaminase (ADA) and serum-ascitic albumin gradient (SAAG) 1 and 2 week after treatment were also analyzed. Results：The duration of fever, time for abdominal pain remission and ascites elimination as well as the incidence rate of intestinal obstruction in the observation group were significantly decreased compared with those of the control group (P＜0.01). No differences were observed in the levels of CRP, ADA and SAAG between two groups at the time point of 1 week after treatment (P>0.05), but the levels of CRP and ADA were significant lower, while SAAG level was singnificantly higher in the observation group than that of the control group at the time point 2-week after treatment (P＜0.05). Conclusions：Systemic therapy combination with intraperitoneal perfusion with antituberculotic drugs is beneficial for the healing of tuberculous peritonitis, and along with defibrase can effectively lessen adhesion formation, thus reducing the incidence of adhesive intestinal obstruction.